Evolus/$EOLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evolus
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
- Ticker
- $EOLS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 353
- Headquarters
- Newport Beach, United States
- Website
- www.evolus.com
Evolus Metrics
BasicAdvanced
$536m
-
-$0.53
1.36
-
Price and volume
Market cap
$536m
Beta
1.36
52-week high
$8.43
52-week low
$3.86
Average daily volume
934k
Financial strength
Current ratio
1.697
Quick ratio
1.089
Long term debt to equity
-524.968
Total debt to equity
-533.295
Interest coverage (TTM)
-1.27%
Profitability
EBITDA (TTM)
-11.723
Gross margin (TTM)
66.74%
Net profit margin (TTM)
-10.85%
Operating margin (TTM)
-6.51%
Effective tax rate (TTM)
-1.94%
Revenue per employee (TTM)
$900,000
Management effectiveness
Return on assets (TTM)
-5.40%
Return on equity (TTM)
138.57%
Valuation
Price to revenue (TTM)
1.673
Price to book
-17.35
Price to tangible book (TTM)
-17.35
Price to free cash flow (TTM)
-20.34
Free cash flow yield (TTM)
-4.92%
Free cash flow per share (TTM)
-0.399
Growth
Revenue change (TTM)
13.87%
Earnings per share change (TTM)
-45.89%
3-year revenue growth (CAGR)
23.35%
3-year earnings per share growth (CAGR)
-23.54%
What the Analysts think about Evolus
Analyst ratings (Buy, Hold, Sell) for Evolus stock.
Evolus Financial Performance
Revenues and expenses
Evolus Earnings Performance
Company profitability
Evolus News
AllArticlesVideos
Evolus Q2 Earnings Call Highlights
MarketBeat1 week ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire1 month ago
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.